The [ 14 C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kgAlthough Cannabis is the most widely abused substance, the addictive potentials of cannabinoid drugs have not been, to date, completely elucidated. Indeed, experimental studies on cannabinoid abuse have been partially limited by difficulties in maintaining stable rates of self-administration of these drugs by laboratory animals. Several factors, including the slow onset of cannabinoid action (Mansbach et al. 1996), aversive qualities (Mallet and Beninger 1998), and negative effects of cannabinoids on learning and memory (Lichtman and Martin 1996; Brodkin and Moerschbaecher 1997) may contribute for the failure of these drugs to be readily self-administered by laboratory animals.There is, however, evidence that cannabinoids exert neurochemical actions on the central reward pathways similar to those produced by addictive drugs (for review see Gardner and Vorel 1998). In particular, intravenous administration of ⌬ 9 -tetrahydrocannabinol (THC) or the synthetic cannabinoid agonist WIN 55212-2 increase extracellular dopamine levels in the shell of the rat nucleus accumbens (Tanda et al. 1997), an effect that resembles those produced by psychomotor stimulants, opiates, and nicotine (Pontieri et al. 1995. This effect is antagonized by blockade of cannabinoid receptors or 1 opioid receptors in the ventral tegmental area (Tanda et al. 1997) and is associated with increased firing of ventral tegmental dopamine neurons ). Moreover, pharmacologically-induced withdrawal from cannabinoid drugs produces neurochemical changes within the limbic system that are similar to those seen with drugs abuse (Rodriguez de Fonseca et al. 1997;Diana et al. 1997). Address correspondence to: Dr. Francesco E. Pontieri, Department of Neuroscience, University La Sapienza, Viale dell'Università, 30, 00185 Roma, Italy.Received January 14, 1999; revised April 29, 1999; accepted May 20, 1999. 774 F.E. Pontieri et al.N EUROPSYCHOPHARMACOLOGY 1999 -VOL . 21 , NO . 6 The [14 C]2-deoxyglucose method (Sokoloff et al. 1977) for measuring local rates of cerebral glucose utilization is a powerful means with which to identify the effects of pharmacological treatments on brain functional activity. Previous reports indicate that acute intravenous administration of several drugs of abuse, such as psychomotor stimulants, morphine, and nicotine, consistently increases glucose utilization in the shell of the rat nucleus accumbens (Pontieri et al. 1994Orzi et al. 1996). In the present study, the [ 14 C]2-deoxyglucose method was applied to map brain areas of altered functional activity associated with the acute administration of the synthetic cannabinoid agonist WIN 55212-2 in the rat. The drug was injected ...